Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial

Puntos clave

• Fecal microbiota transplantation may improve responses in patients with metastatic renal cell carcinoma.
• The overall response rate was assessed, revealing promising outcomes in treatment groups.
• Randomized phase 2 trial design with comparative analysis of treatment efficacy and safety.
• This study emphasizes potential synergistic effects, indicating combined therapy may enhance treatment results.